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Background: Rapid risk stratification is a core task in emergency medicine. Identifying patients at high and low risk
shortly after admission could help clinical decision-making regarding treatment, level of observation, allocation of
resources and post discharge follow-up. The purpose of the present study was to determine short-, mid- and
long-term mortality by plasma measurement of copeptin in unselected admitted patients.
Method: Consecutive patients >40-years-old admitted to an inner-city hospital were included. Within the first
24 hours after admission, a structured medical interview was conducted and self-reported medical history was
recorded. All patients underwent a clinical examination, an echocardiographic evaluation and collection of blood
for later measurement of risk markers.
Results: Plasma for copeptin measurement was available from 1,320 patients (average age 70.5 years, 59.4% women).
Median follow-up time was 11.5 years (range 11.0 to 12.0 years). Copeptin was elevated (that is, above the 97.5
percentile in healthy individuals).
Mortality within the first week was 2.7% (17/627) for patients with elevated copeptin (above the 97.5 percentile,
that is, >11.3 pmol/L) compared to 0.1% (1/693) for patients with normal copeptin concentrations (that is, ≤11.3
pmol/L) (P <0.01). Three-month mortality was 14.5% (91/627) for patients with elevated copeptin compared
to 3.2% (22/693) for patients with normal copeptin. Similar figures for one-year mortality and for the entire
observation period were 27.6% (173/627) versus 8.7% (60/693) and 82.9% (520/527) versus 57.5% (398/693)
(P <0.01 for both), respectively.
Using multivariable Cox regression analyses shows that elevated copeptin was significantly and independently
related to short-, mid- and long-term mortality. Adjusted hazard ratios were 2.4 for three-month mortality, 1.9 for
one-year mortality and 1.4 for mortality in the entire observation period.
Conclusions: In patients admitted to an inner-city hospital, copeptin was strongly associated with short-, mid- and
long-term mortality. The results suggest that rapid copeptin measurement could be a useful tool for both disposition
in an emergency department and for mid- and long-term risk assessment.
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An increasing number of patients are referred to emer-
gency departments [1]. Prolonged waiting times and asso-
ciated crowding have been shown to increase mortality
[2,3], and rapid risk stratification is, therefore, a core task
in emergency medicine. Identifying patients at high and
low risk shortly after admission could help decision-
making in the prioritization of patients, treatment, level of
observation and post-discharge follow-up. Copeptin is the
C-terminal fragment of provassopressin and is presumably
co-secreted with arginine vasopressin from the hypothal-
amus [4]. Copeptin concentrations in plasma increase as a
response to physiological stress [5] and have been shown
to have prognostic value in several disease entities, such
as cardiovascular disease [6-17], head injury [18-20], pul-
monary disease [21-24] and shock [25-28], but also in
older people with nonspecific complaints [29]. Copeptin
could, therefore, be a marker for adverse outcome in unse-
lected patients admitted to a hospital, and its measure-
ment could optimize both short- and long-term risk
stratification in an emergency department. The purpose of
the present study was to determine short-, mid-, and long-
term mortality according to copeptin plasma concentra-
tions in unselected admitted patients. Moreover, the prog-
nostic importance of copeptin measurement in different
disease entities was examined.
Methods
Patients
Patients were recruited from the Copenhagen Hospital
Heart Failure (CHHF) study [30]. The primary aim of
CHHF was to investigate if N-terminal pro-brain natri-
uretic peptide (NT-proBNP) could be used as a screen-
ing tool for heart failure in unselected patients admitted
to a hospital. Secondary aims were to follow a cohort of
adult patients admitted to hospital, irrespective of diag-
nosis. The CHHF study included all patients >40 years
of age admitted to medical or surgical departments at
Amager Hospital, Copenhagen, Denmark, between 1
April 1998 and 31 March 1999. In this period 3,644 pa-
tients >40-years-old were admitted to the hospital. Dur-
ing the last 10 months of the study blood samples were
drawn from patients who gave written informed consent
to participate in the study (n = 2,230), The same two
dedicated physicians performed the screenings and ex-
aminations during the entire study period.
Within the first 24 hours after admission, a structured
medical interview was conducted and self-reported medical
history was recorded. Additional information from previ-
ous hospital admissions was obtained from the patient files.
Furthermore, all patients went through a clinical examin-
ation and an echocardiographic evaluation of the heart.
After discharge, information regarding primary final
diagnosis was collected from patient files. Based on thisinformation, patients were categorized into eight separ-
ate disease categories where more rare causes for admis-
sion were categorized as ‘other’ (diagnoses of rheumatology
(n = 10), nephrology (n = 5), endocrinology (n = 42); and
non-specific diagnoses, such as dehydration, social causes,
and drug abuse) (see Table 1).
Information about death was obtained from the
Danish Centralized Civil Register using the patients’
unique national Civil Registration Numbers. The Danish
Central Office of Civil Registration records the vital
status of all residents.
Blood samples
Blood samples were drawn between 8.00 am and 10.00 am
within 24 hours of admission. Samples were centrifuged
for 10 minutes at 3,000 rpm. Plasma was stored at –80°C
until analysis and only thawed once.
Hemoglobin, C-reactive protein (CRP), creatinine, so-
dium, and potassium were obtained by standard methods.
The glomerular filtration rate was estimated (eGFR) by
age, creatinine, and sex using the Modification of Diet in
Renal Disease (MDRD) formula [31].
NT-proBNP measurements were taken consecutively
during the last 10 months of the study using an ELISA –
a two-step sandwich assay with streptavidin-coated mi-
crotiter plates (Roche, Basel, Switzerland) [32]. Plasma
concentrations of copeptin (ultra-sensitive) were mea-
sured in November 2012 on the Kryptor Compact Plus
platform (BRAHMS, Hennigsdorf, Germany). The inter-
assay coefficients of variation were 18.3% for 1.4 pmol/L,
6.8% for 9.3 pmol/L and less than 3% for concentra-
tions >18 pmol/L [33]. Reference values of copeptin are
based on previously published data, where elevated copep-
tin was defined as plasma levels above the 97.5 percentile
of copeptin concentration in healthy controls (11.3 pmol/L)
[4]. In the following, copeptin levels >11.3 pmol/L will be
defined as elevated.
Ethics
The study complied with the Declaration of Helsinki II
and was approved by the regional ethics committee of
Copenhagen. Following the guidelines for provision of
oral and written information, all patients gave written in-
formed consent to participate in the study.
Statistics
Patients were grouped in three different ways for presenta-
tion of data and for statistical analyses: 1, elevated (that is,
>11.3 pmol/L = 97.5-percentile in healthy individuals) ver-
sus normal copeptin concentrations; 2, quartiles of copep-
tin; 3, very low (that is, <5-percentile) versus very high
(>95-percentile) copeptin concentrations. Associations be-
tween categories of variables were measured by the χ2 –
test or trend test, and Student’s t-test was used for
Table 1 Patients included and not included in the study
Baseline variables Included patients Not included patients P-value
(number = 1,320) (number = 2,309a
Demographics
Age, years 70.5 70.6 0.76
Mean (95% CI) (69.7 to 71.3) (70.0 to 71.2)
Male gender, number (%) 536 (41) 956 (41) 0.61
Medical history
Heart failure, number (%) 160 (12) 244 (13) 0.62
Ischemic heart disease, number (%) 281 (21) 369 (19) 0.15
Previous myocardial infarction, number (%) 132 (10) 224 (12) 0.13
Hypertension, number (%) 349 (27) 455 (24) 0.08
Lung disease, number (%) 255 (19) 365 (19) 0.83
Liver disease, number (%) 39 (3) 58 (3) 0.91
Diabetes, number (%) 141 (11) 220 (11) 0.47
Discharge diagnoses
Heart disease, number (%) 260 (20) 384 (17)
Orthopedic disease, number (%) 211 (16) 349 (15)
Gastrointestinal disease, number (%) 168 (13) 287 (12)
Hematological/oncological, number (%) 85 (6) 154 (7) 0.19
Pulmonary disease, number (%) 85 (6) 150 (7)
Neurological disease, number (%) 133 (10) 258 (11)
Infectious disease, number (%) 187 (191) 329 (14)
Other diseases, number (%) 191 (15) 398 (17)
aBaseline data only available in 2,309 of the 2,324 not included patients (99%).
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lustrate survival curves and Cox proportional hazard
model was used for initial univariate comparisons. Multi-
variable comparisons were performed using a Cox propor-
tional hazard model (fitted by backward elimination using
a threshold of P <0.1 for elimination) after checking as-
sumptions of proportionality. Cox analyses were made for
three-month (short-term) mortality, one-year (mid-term)
mortality and mortality during the entire observation
period (long-term). Due to the, by default, low mortality
during the first week, Cox survival analyses were not made
for one-week mortality. Areas under the curve (AUC) were
calculated for copeptin in relation to one-week, three-
month and one-year mortality, and mortality over the
entire study period. C-statistics were calculated for all vari-
ables with independent prognostic value. Continuous
variables are summarized as means and 95% confidence
intervals (CI), while categorical data are summarized as fre-
quencies and percentages. Statistical calculations were
done with SPSS version 20.0 (SPSS Inc., Chicago, IL, USA).
Results
Blood samples were collected from 2,294 patients. Plasma
for copeptin measurement was available from 1,320patients (36% of admitted patients) and these constitute
the study population in the present paper. The remaining
patients (n = 974) did not have spare plasma for copeptin
analysis, but were randomly spread out across the entire
study period. Patients included were 70.5 years old on
average (95% CI 69.7 to 71.3 years), 59.4% were women
and the mean admission time was 6.2 days (95% CI 5.6 to
6.7 days). The patients included in the present analysis
were comparable to the ones without plasma samples.
There was no difference between included versus excluded
regarding baseline variables, comorbidity or discharge
diagnoses (Table 1); however, mortality was slightly lower
in the included patients (hazard ratio (HR) 0.89, 95% C.I.
0.82 to 0.97).
Median plasma copeptin in the total population was
10.5 pmol/L (range 1 to 725 pmol/L, interquartile range
5.2 to 24.1 pmol/L). The median value was higher in
male than in female patients (11.4 pmol/L versus 9.7
pmol/L, P = 0.02). Both male and female median values
of copeptin were higher than previously reported values
in healthy men and women [4] (5.2 pmol/L and 3.7
pmol/L, P <0.01 for both). In 47.5% (627/1,320) of the
patients, the plasma copeptin level was higher than the
previously reported 97.5 percentile in healthy subjects.
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this population was 89 pmol/L, 125 pmol/L and 211
pmol/L, respectively.
Baseline variables of the patients (demographics, vital
parameters, symptoms, medical history and laboratory
examinations) in relation to elevated or normal plasma
concentration of copeptin are presented in Table 2. Age,
systolic and diastolic blood pressure, heart rate, history
of heart failure, New York Heart Association (NYHA)
class III-IV, ejection fraction, hemoglobin, eGFR, NT-
proBNP and left ventricular ejection fraction differed
significantly between the patients with elevated plasma
copeptin compared to patients with normal plasma
copeptin. Copeptin showed a significant but weak correl-
ation with other known markers of mortality (NT-
proBNP: r2 = 0.14, P <0.001; eGFR: r2 = 0.10, P <0.001;
age: r2 = 0.04, P <0.001; hemoglobin: r2 = 0.02, P <0.001;
potassium: r2 = 0.02, P <0.001; CRP: r2 = 0.01, P = 0.03),





Age, years, mean (95% CI) 66.3 (65
Male gender, number (%) 264
Vital signs
Systolic blood pressure, mmHg, mean (95% CI) 150 (14
Diastolic blood pressure, mmHg, mean (95% CI) 86 (84
Heart rate, b/min, mean (95% CI) 86 (84
Medical history
Heart failure, number (%) 58
Ischemic heart disease, umber (%) 136
Previous myocardial infarction, number (%) 63
Hypertension, number (%) 183
Lung disease, number (%) 144
Liver disease, number (%) 20
Diabetes, number (%) 65
NYHA III-IV, n (%) 32
Laboratory examinations
Sodium mmol/L, mean (95% CI) 137 (13
Potassium, mmol/L, mean (95% CI) 4.0 (3.
Hemoglobin, mmol/L, mean (95% CI) 8.4 (8.
C-reactive protein, mg/L, mean (95% CI) 656 (53
e-GFR, ml/min, mean (95% CI) 92 (90
NT proBNP, pmol/L, mean (95% CI) 147 (12
Ejection fraction, %, mean (95% CI) 60.3 (59
b/min, beats per minute; CI, confidence interval; eGFR, estimated glomerular filtratio
Heart Association.Median follow-up time was 11.5 years, (range 11.0 to
12.0 years). Complete follow-up was possible for all ex-
cept one patient after one year and for all except eight
patients during the entire observation period. The rea-
son for missing information was emigration. All nine pa-
tients were censored at time of immigration. One-week
mortality was 1.4% (18/1,320), three-month mortality
was 8.6% (113/1,320), one-year mortality was 17.7%
(233/1,320 patients), and 69.3% (915/1,320 patients) died
during the entire study period.
Figure 1 shows Kaplan-Meier curves for survival of pa-
tients with normal and elevated levels of copeptin (a),
for quartiles of copeptin (b), and for patients with very
low (<5-percentile) and very high copeptin (>95-percent-
ile) (c). Mortality within the first week, three-month
mortality, one-year mortality, and mortality for the en-
tire observation period for different groupings of copep-
tin appear in Table 3. Copeptin was strongly related to
mortality independent of grouping of copeptin andptin Copeptin P-value
mol/L >11.3 pmol/L
r= 693) (number = 627)
.1-67.2) 75.3 (74.3-76.3) <0.01
(38) 272 (43) 0.05
8-153) 147 (144-149) 0.01
-87) 81 (80-83) <0.01
-97) 87 (86-89) <0.01
(8) 102 (16) <0.01
(20) 145 (23) 0.11
(9) 69 (11) 0.20
(27) 166 (27) 0.92
(21) 111 (18) 0.18
(3) 19 (3) 0.86
(9) 76 (12) 0.12
(5) 72 (11) <0.01
7-137) 137 (136-137) 0.06
9-4.0) 4.0 (3.9-4.0) 0.61
3-8.4) 7.9 (7.8-8.0) 0.01
2-780) 839 (721-956) 0.05
-95) 74 (72-77) 0.01
5-164) 499 (426-572) 0.01
.5-61.0) 57.0 (56.0-57.9) 0.01




































Copeptin < 5.2 pmol/L
Copeptin 5.2-10.5 pmol/L
Copeptin 10.5-24.1 pmol/L
Copeptin > 24.1 pmol/L



















Copeptin > 88.6 pmol/L
Figure 1 Kaplan-Meier plots for patients with elevated versus normal copeptin (a), quartiles of copeptin (b), very high versus very low
copeptin (c).
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seen for very high versus very low copeptin and short
observation time.
Using multivariable Cox regression analyses, we exam-




Normal Elevated Lowest Highe
One week 0.1% 2.7% 0 % 4.2%
0-3 months 3.2% 14.5% 3.0% 20.0
0-12 months 8.7% 27.6% 7.6% 34.8
Entire study 57.5% 82.9% 50.9% 88.2elevated values of copeptin. All 20 variables from Table 3
were tested as covariates. After backward elimination,
NT-proBNP (log-transformed), gender, age, liver disease,
potassium and hemoglobin remained in the fully adjusted




0% 10.6% P <0.01 for all
% 1.5% 43.9% P <0.01 for all
% 3.0% 54.5% P <0.01 for all
% 50.0% 89.4% P <0.01 for all
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copeptin and copeptin levels above the 95th-percentile
were significantly and independently related to short-,
mid- and long-term mortality in the entire population
when the above-mentioned variables were included in
the model.
HRs for patients with elevated copeptin in the differ-
ent disease categories are shown in Figure 2. The HR for
death was highest short-term, but almost all HRs were
significantly different from 1. Figure 3 illustrates Kaplan-
Meier curves for overall survival according to discharge
diagnosis and elevated copeptin (>11.3 pmol/L).
Receiver operating characteristic (ROC) analyses
show that the AUC for copeptin to predict one-week,
short-, mid- and long-term mortality was 0.84 (95% CI
0.77 to 0.92), 0.75 (95% CI 0.70 to 0.80), 0.71 (95% CI
0.67 to 0.74) and 0.70 (0.67 to 0.73), respectively. Com-
paring a model with age, gender and comorbidity
(model 1) to a model containing all variables included
in the final Cox model (that is, NT-proBNP (log-trans-
formed), gender, age, liver disease, potassium and
hemoglobin) (model 2) and to the fully adjusted model
with copeptin added (model 3), we found a significant
increase in AUCs for one-week mortality (0.70 (95%
C.I. 0.65 to 0.76) versus 0.80 (95% CI 0.73 to 0.88) ver-
sus 0.85 (95% CI 0.77 to 0.93), P = 0.04) and for three-
month mortality (0.72 (95% C.I. 0.70 to 0.75) versus
0.77 (95% CI 0.73 to 0.81) versus 0.79 (95% CI 0.75 to
0.83), P = 0.01), respectively. There was no significant
effect on AUCs of adding copeptin to the fully adjusted
model for one-year mortality or for the entire observa-
tion period.Table 4 Unadjusted and adjusted hazard ratios associated wi
mortality
Unadjusted
hazard ratio (95% C
3 months First year
Quartiles
Quartile 1 (ref.) <5.2 pmol/L 1 1
Quartile 2 5.2-10.5 pmol/L 1.10 (0.47-2.59) 1.33 (0.79-2.24)
Quartile 3 10.5-24.1 pmol/L 2.66 (1.28-5.52) 2.53 (1.58-4.04)
Quartile 4 >24.1 pmol/L 7.40 (3.80-14.39) 5.62 (3.65-8.66)
Elevated copeptin (>11.3 pmol/L)
Normal copeptin (ref.) 1 1
Elevated copeptin 4.90 (3.08-7.81) 3.61 (2.70-4.85)
95%-percentile vs. 5%-percentile
5%-percentile (ref.) <2.4 pmol/L 1 1
95%-percentile 40.43 (5.51-296.90) 29.36 (7.07-121.99
Per 1 increase in log copeptin 6.66 (4.63-9.57) 4.24 (3.29-5.47)
aN-terminal pro-brain natriuretic peptide (log-transformed), gender, age, liver diseasDiscussion
To the best of our knowledge, this study is the first to de-
termine the prognostic value of copeptin measurement in
unselected patients ≥40- years old admitted to both med-
ical and surgical departments. Copeptin measurement had
a strong and independent prognostic importance for all
patients and seems not to be related to any specific diag-
nosis. Patients with low copeptin concentrations had an
excellent short-term prognosis with no fatal outcomes
within the first week and only very few deaths within three
months. On the other hand, high copeptin concentrations
identified a subgroup of patients with a very high risk of
short-term mortality.
Previous studies
The cut-off level for elevated copeptin in the present
analysis is based on the 97.5 percentile from the original
assay article(4). Recently Keller et al. published a slightly
higher 97.5 percentile (that is, 13 pmol/L) based on data
from the Gutenberg health study [34]. This population is
however not a healthy population but a random popula-
tion sample also including patients with a broad spectrum
of different conditions and diseases. This might explain
the slightly higher cut-off value in this population and is
the reason why we chose to use the original published
cut-off values for elevated copeptin.
Our findings corroborate and extend previous studies
investigating the prognostic role of copeptin in different
settings. In patients with ischemic heart disease, copep-
tin has been shown to have a high prognostic value with
adjusted HRs comparable to the results from the present
study [6,12]. Similar results have been reported fromth copeptin levels on short-, mid-, and long-term
Adjusteda
I) hazard ratio (95% CI)
Total
study period
3 months First year Total
study period
1 1 1 1
1.39 (1.13-1.70) 0.70 (0.29-1.69) 0.87 (0.50-1.50) 1.01 (0.81-1.26)
2.14 (1.76-2.61) 1.40 (0.66-2.96) 1.27 (0.74-2.08) 1.21 (0.98-1.51)
3.52 (2.91-4.27) 2.48 (1.19-5.15) 1.95 (1.20-3.17) 1.65 (1.33-2.06)
1 1 1 1
2.28 (2.00-2.60) 2.44 (1.47-4.08) 1.85 (1.33-2.58) 1.36 (1.17-1.57)
1 1 1 1
) 5.41 (5.53-8.29) 7.09 (0.92-54.86) 4.99 (1.16-21.50) 1.60 (1.00-2.58)
2.76 (2.41-3.15) 3.24 (2.07-5.08) 1.96 (1.43-2.68) 1.52 (1.29-1.79)
e, potassium, and hemoglobin remained in the model. CI, confidence interval.
Figure 2 Unadjusted hazard ratios associated with elevated
copeptin on three month-, one year-, and entire study mortality
in different disease entities.
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seems to be an even stronger predictor for outcome than
natriuretic peptides [7,17]. In patients with neurological
disease, such as ischemic stroke [10,14,15], intracereberal
hemorrhage [18,20] and traumatic head injury [19],
copeptin seems to be an excellent marker for both neuro-
logical outcome and short- and mid-term mortality. The
same prognostic value of copeptin is seen in patients with
lung infections [21,23] and chronic obstructive lung dis-
ease [25,24,35]. Also, in non-disease specific conditions,
such as shock [25-28,36], and in surgical patients [37]
copeptin seems to be a valuable marker for outcome. Re-
cently, Nickel and coworkers have published a study de-
scribing the short-time prognostic role of copeptin in
patients presenting in the emergency department with
non-specific complaints. In accordance with the present
study they found a strong and independent prognostic
value of copeptin [29].Strengths and limitations
The strengths of this study are the size of the cohort, its
prospective and relative unselected nature, and the long
follow-up period. A cohort of unselected patients admit-
ted to a hospital is unique and makes it possible to test
the role of copeptin under various medical and surgical
conditions. The heterogeneity of the different disease
subgroups and limited number of patients within each
group does not allow firm conclusions but serves to gen-
erate further hypotheses. Only all-cause mortality was
registered. Causes of death and admissions would have
been other interesting endpoints, but their validity is
suboptimal in the registries. The study was a single cen-
ter study and this could potentially cause problems with
generalizability. This concern is, however, partly coun-
tered by the fact that the hospital is placed in a part of
Copenhagen that includes both high income and low in-
come areas as well as inner city and surburban /country
areas. Blood samples were stored for 12 years at –80°C,
which could introduce a problem with degradation.
However, stability analyses of copeptin have shown that
copeptin is a very stable peptide, and no degradation is
seen after several cycles of freeze/thaw or after as much
as seven days at room temperature [4,33]. Even if there
was some degree of degradation of copeptin over the 12
years, this does not pose a problem in the overall inter-
pretation concerning risk. The measured concentrations
are most likely underestimated and would have been
slightly higher if measured in fresh samples.
Blood was available from only 53% of the originally in-
cluded patients, the main reason being a lack of spare
plasma after blood had been used for other purposes.
However, we did not identify any systematic reason for
this selection, and there were no differences in baseline
variables or mortality between included and not included
patients. Some selection bias in the original cohort was in-
evitable due to missing informed consent from confused,
mentally disabled and frail patients. The mean age of the
population in the study is high (74 years) and there was a
high prevalence of comorbidity. Therefore, the results of
this study cannot without caution be extrapolated to
younger or non-hospitalized populations.
Clinical implications
The results of this study suggest that copeptin could be a
very useful tool for disposition in an emergency depart-
ment. Knowing that patients had a seven-day mortality of
more than 10% or a one-year mortality of less than 3%
might influence the clinician’s decisions regarding observa-
tion and treatment in the emergency department. Studies
evaluating an intervention (that is, observation, admission
or discharge) following measurement of copeptin could
show if the findings in the present study could be trans-

















































































































































Figure 3 Kaplan-Meier curves illustrating the prognostic value of having elevated copeptin for different disease entities.
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In patients ≥40 years of age admitted to an inner-city
hospital, copeptin in plasma was strongly associated with
short-, mid- and long-term mortality. Having very highor very low copeptin identifies a subgroup of patients,
respectively, with very poor and very good short-term
prognosis. Copeptin seems to be valuable in the most
frequent disease entities.
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